Citi analyst Yigal Nochomovitz initiates coverage on Mersana (NASDAQ: MRSN) with a Buy rating and a price target of $5.00.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot New Coverage New Coverage

Form SC 13G/A Mersana Therapeutics, Filed by: Nextech Crossover I GP S.a r.l.November 14, 2024 5:46 PM Form SC 13G/A Mersana Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.November 14, 2024 6:04 AM Form 10-Q Mersana Therapeutics, For: Sep 30November 13, 2024 8:51 AM Form 8-K Mersana Therapeutics, For: Nov 13November 13, 2024 7:27 AM Mersana Therapeutics (MRSN) Misses Q3 EPS by 18cNovember 13, 2024 7:06 AM Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 7:01 AM